Peginterferon beta-1a
Clinical data
Trade namesPlegridy, Plegridy Pen
Other namesBIIB-017
AHFS/Drugs.comMonograph
MedlinePlusa614059
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
Drug classAntineoplastic agent
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[2]
  • US: ℞-only[3]
  • EU: Rx-only[4]
  • In general: ℞ (Prescription only)
Identifiers
  • 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC913H1417N246O256PS7 [C2H4O]n
Molar mass44000 g·mol−1

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[3][4]

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.[3][4]

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.[5][4]

Medical uses

In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[3]

In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[4]

References

  1. ↑ "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.
  2. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  3. 1 2 3 4 "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.
  4. 1 2 3 4 5 "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.